1. Home
  2. NUVB vs EVLV Comparison

NUVB vs EVLV Comparison

Compare NUVB & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • EVLV
  • Stock Information
  • Founded
  • NUVB 2018
  • EVLV 2013
  • Country
  • NUVB United States
  • EVLV United States
  • Employees
  • NUVB N/A
  • EVLV N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • EVLV Computer peripheral equipment
  • Sector
  • NUVB Health Care
  • EVLV Technology
  • Exchange
  • NUVB Nasdaq
  • EVLV Nasdaq
  • Market Cap
  • NUVB 1.1B
  • EVLV 1.2B
  • IPO Year
  • NUVB N/A
  • EVLV N/A
  • Fundamental
  • Price
  • NUVB $3.28
  • EVLV $8.16
  • Analyst Decision
  • NUVB Strong Buy
  • EVLV Strong Buy
  • Analyst Count
  • NUVB 6
  • EVLV 4
  • Target Price
  • NUVB $8.17
  • EVLV $8.88
  • AVG Volume (30 Days)
  • NUVB 6.7M
  • EVLV 2.9M
  • Earning Date
  • NUVB 11-05-2025
  • EVLV 08-14-2025
  • Dividend Yield
  • NUVB N/A
  • EVLV N/A
  • EPS Growth
  • NUVB N/A
  • EVLV N/A
  • EPS
  • NUVB N/A
  • EVLV N/A
  • Revenue
  • NUVB $14,355,000.00
  • EVLV $121,011,000.00
  • Revenue This Year
  • NUVB $332.80
  • EVLV $31.07
  • Revenue Next Year
  • NUVB $360.12
  • EVLV $17.67
  • P/E Ratio
  • NUVB N/A
  • EVLV N/A
  • Revenue Growth
  • NUVB 900.35
  • EVLV 36.64
  • 52 Week Low
  • NUVB $1.54
  • EVLV $2.04
  • 52 Week High
  • NUVB $4.09
  • EVLV $8.91
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 58.18
  • EVLV 54.16
  • Support Level
  • NUVB $3.20
  • EVLV $7.76
  • Resistance Level
  • NUVB $3.41
  • EVLV $8.81
  • Average True Range (ATR)
  • NUVB 0.27
  • EVLV 0.43
  • MACD
  • NUVB -0.03
  • EVLV -0.05
  • Stochastic Oscillator
  • NUVB 33.55
  • EVLV 39.35

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: